| Name | 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzimidazol-2-one |
|---|---|
| Synonyms |
1,3-Dihydro-5-[3-[4-(phenylmethyl)-H-benzimidazol-2-one
2H-Benzimidazol-2-one, 1,3-dihydro-5-[3-[4-(phenylmethyl)-1-piperidinyl]-1-propyn-1-yl] tcs 46b TCS 46B 5-(3-(4-Benzylpiperidin-1-yl)prop-1-yn-1-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one 5-(3-(4-benzylpiperidin-1-yl)prop-1-yn-1-yl)-1H-benzo[d]imidazol-2(3H)-one |
| Description | TCS 46b (Compound 46b) is a potent, selective and orally active NMDA NR1A/2B receptor antagonist with an IC50 of 5.3 nM[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 5.3 nM (NR1A/2B), 35 μM (NR1A/2A), >100 μΜ (NR1A/2C), 0.5 μM (α-1 adrenergic receptor), 2.6 μM (dopamine D2)[1] |
| In Vivo | TCS 46b (Compound 46b; 10 and 30 mg/kg; p.o. or i.p.; once) 在 6-OHDA 损伤大鼠中增强左旋多巴的作用[1]。 Animal Model: Sprague−Dawley rats, 6-hydroxydopamine-lesioned (6-OHDA) rat model[1] Dosage: 10 and 30 mg/kg Administration: PO or IP, once Result: Showed significant potentiation of the effects of L-DOPA in this model. |
| References |
| Molecular Formula | C22H23N3O |
|---|---|
| Molecular Weight | 345.44 |
| Exact Mass | 345.18400 |
| PSA | 51.89000 |
| LogP | 3.10030 |
| Storage condition | -20°C |